HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Discontinuation of furosemide decreases PaCO(2) in patients with COPD.

AbstractSTUDY OBJECTIVE:
To evaluate whether the discontinuation of furosemide treatment resulted in a decrease in PaCO(2) and an increase in daytime and nocturnal oxygenation.
BACKGROUND:
Furosemide is widely prescribed in patients with COPD for the treatment of peripheral edema. It is known that furosemide causes a metabolic alkalosis. A diminished chemoreceptor stimulation may cause a decreased alveolar ventilation.
DESIGN:
Randomized, double-blind, placebo-controlled, crossover trial.
SETTING:
Department of Pulmonology, Rijnstate Hospital Arnhem, the Netherlands.
PATIENTS:
Twenty patients with stable COPD (10 men; median age, 70 years [range, 58 to 81 years]; FEV(1) 35% predicted [range, 19 to 70% predicted]). Subjects were included if they had received furosemide, 40 mg/d, for the treatment of peripheral edema for at least a month and if they had a mean nocturnal arterial oxygen saturation (SaO(2)) < 92%. Patients with cardiac left and/or right ventricular dysfunction, sleep apneas, and patients receiving other diuretics, angiotensin-converting enzyme inhibitors, potassium or chloride replacement therapy, or long-term oxygen treatment were excluded.
INTERVENTION:
Furosemide was discontinued for 1 week and replaced by placebo treatment in the first or the second week.
MEASUREMENTS AND RESULTS:
Ventilation, daytime arterial blood gas levels, and nocturnal SaO(2) were measured at baseline, after 1, and after 2 weeks. Sixteen subjects completed the study. Ventilation increased from 10.4 L/min (range, 6.7 to 15.4 L/min) at baseline to 11.6 L/min (range, 8.7 to 14.0 L/min) after discontinuation of furosemide (p < 0.05). PaCO(2) decreased from 45 mm Hg (range, 35 to 64 mm Hg) to 41 mm Hg (range, 32 to 61 mm Hg; p < 0.01). Daytime and nocturnal oxygenation did not improve.
CONCLUSIONS:
Although it does not improve oxygenation, the discontinuation of furosemide decreases PaCO(2) in patients with COPD.
AuthorsFolkert Brijker, Yvonne F Heijdra, Frank J J van den Elshout, Hans Th M Folgering
JournalChest (Chest) Vol. 121 Issue 2 Pg. 377-82 (Feb 2002) ISSN: 0012-3692 [Print] United States
PMID11834646 (Publication Type: Clinical Trial, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
Chemical References
  • Diuretics
  • Furosemide
  • Carbon Monoxide
Topics
  • Aged
  • Aged, 80 and over
  • Body Fluids (metabolism)
  • Carbon Monoxide (analysis)
  • Cross-Over Studies
  • Diuretics (pharmacology)
  • Double-Blind Method
  • Edema (drug therapy)
  • Female
  • Furosemide (pharmacology)
  • Hemostasis (drug effects)
  • Humans
  • Male
  • Middle Aged
  • Oxygen Consumption (drug effects)
  • Partial Pressure
  • Pulmonary Disease, Chronic Obstructive (physiopathology)
  • Respiratory Function Tests

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: